Q-omics provides the consensus-scored COL23A1 profile across patient tissues and cancer cell-line models. COL23A1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, COL23A1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, COL23A1 RNA expression shows 14,364 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where COL23A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL23A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL23A1 survival associations across molecular data types. COL23A1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL23A1 RNA expression–survival associations across cancer types. High COL23A1 expression shows unfavorable associations in UCEC, MESO and UVM, but favorable associations in KIRC, HNSC and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for COL23A1 RNA expression.
This table summarizes COL23A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COL23A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL23A1 shows lower tumor expression in THCA, KICH, BRCA and COAD and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher COL23A1 RNA expression in tumor versus normal tissue (log2 FC = +5.731, t-test p < 0.001).
This table shows molecular features associated with COL23A1 in patient tissues and cancer cell lines. In patient samples, COL23A1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, COL23A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
